|
1
|
Wang Y, Zhu H, Madabushi R, Liu Q, Huang S, Zineh I. Model‐Informed Drug Development: Current US Regulatory Practice and Future Considerations. Clin Pharmacol Ther 2019; 105:899-911. [DOI: 10.1002/cpt.1363] [Citation(s) in RCA: 89] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2018] [Accepted: 12/26/2018] [Indexed: 11/10/2022]
Affiliation(s)
- Yaning Wang
- Office of Clinical PharmacologyOffice of Translational SciencesUS Food and Drug Administration Silver Spring Maryland USA
| | - Hao Zhu
- Office of Clinical PharmacologyOffice of Translational SciencesUS Food and Drug Administration Silver Spring Maryland USA
| | - Rajanikanth Madabushi
- Office of Clinical PharmacologyOffice of Translational SciencesUS Food and Drug Administration Silver Spring Maryland USA
| | - Qi Liu
- Office of Clinical PharmacologyOffice of Translational SciencesUS Food and Drug Administration Silver Spring Maryland USA
| | - Shiew‐Mei Huang
- Office of Clinical PharmacologyOffice of Translational SciencesUS Food and Drug Administration Silver Spring Maryland USA
| | - Issam Zineh
- Office of Clinical PharmacologyOffice of Translational SciencesUS Food and Drug Administration Silver Spring Maryland USA
| |
Collapse
|